NASDAQ:SMMT - SUMMIT THERAPEU/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SUMMIT THERAPEU/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.46 -0.02 (-1.35 %) (As of 02/18/2020 04:47 AM ET) Add Compare Today's Range$1.41Now: $1.46▼$1.4850-Day Range$1.43MA: $1.53▼$1.7052-Week Range$1.13Now: $1.46▼$2.46Volume51,801 shsAverage Volume70,646 shsMarket Capitalization$46.81 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT Previous Symbol CUSIPN/A CIK1599298 Webhttp://www.summitplc.com/ Phone44-12-3544-3939Debt Debt-to-Equity Ratio0.02 Current Ratio3.26 Quick Ratio3.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$56.50 million Price / Sales0.83 Cash Flow$1.12 per share Price / Cash Flow1.30 Book Value$4.08 per share Price / Book0.36Profitability EPS (Most Recent Fiscal Year)$0.84 Net Income$9.99 million Net Margins-2,107.69% Return on Equity-59.95% Return on Assets-42.26%Miscellaneous Employees61 Outstanding Shares32,100,000Market Cap$46.81 million Next Earnings Date3/25/2020 (Estimated) OptionableOptionable Receive SMMT News and Ratings via Email Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SMMT Rates by TradingView SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions What is SUMMIT THERAPEU/S's stock symbol? SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT." How were SUMMIT THERAPEU/S's earnings last quarter? SUMMIT THERAPEU/S (NASDAQ:SMMT) posted its earnings results on Tuesday, December, 17th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.02. The business earned $0.16 million during the quarter, compared to analyst estimates of $4.07 million. SUMMIT THERAPEU/S had a negative net margin of 2,107.69% and a negative return on equity of 59.95%. View SUMMIT THERAPEU/S's Earnings History. When is SUMMIT THERAPEU/S's next earnings date? SUMMIT THERAPEU/S is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for SUMMIT THERAPEU/S. What price target have analysts set for SMMT? 2 Wall Street analysts have issued twelve-month price targets for SUMMIT THERAPEU/S's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate SUMMIT THERAPEU/S's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S. What is the consensus analysts' recommendation for SUMMIT THERAPEU/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S. Has SUMMIT THERAPEU/S been receiving favorable news coverage? Media headlines about SMMT stock have been trending very negative on Tuesday, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for SUMMIT THERAPEU/S. Who are some of SUMMIT THERAPEU/S's key competitors? Some companies that are related to SUMMIT THERAPEU/S include GlycoMimetics (GLYC), Ovid Therapeutics (OVID), Kezar Life Sciences (KZR), Strongbridge Biopharma (SBBP), Neptune Wellness Solutions (NEPT), NuCana (NCNA), Avenue Therapeutics (ATXI), Spero Therapeutics (SPRO), Akorn (AKRX), Harrow Health (HROW), Five Prime Therapeutics (FPRX), Abeona Therapeutics (ABEO), Evelo Biosciences (EVLO), Scpharmaceuticals (SCPH) and Obseva (OBSV). What other stocks do shareholders of SUMMIT THERAPEU/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other SUMMIT THERAPEU/S investors own include Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE), Catabasis Pharmaceuticals (CATB), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER) and Martin Midstream Partners (MMLP). Who are SUMMIT THERAPEU/S's key executives? SUMMIT THERAPEU/S's management team includes the folowing people: Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)Ms. Michelle Avery, Director of Investor Relations When did SUMMIT THERAPEU/S IPO? (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. Who are SUMMIT THERAPEU/S's major shareholders? SUMMIT THERAPEU/S's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.59%), Acadian Asset Management LLC (0.41%), First Republic Investment Management Inc. (0.16%) and Virtu Financial LLC (0.05%). Which institutional investors are selling SUMMIT THERAPEU/S stock? SMMT stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Which institutional investors are buying SUMMIT THERAPEU/S stock? SMMT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Republic Investment Management Inc. and Virtu Financial LLC. How do I buy shares of SUMMIT THERAPEU/S? Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is SUMMIT THERAPEU/S's stock price today? One share of SMMT stock can currently be purchased for approximately $1.46. How big of a company is SUMMIT THERAPEU/S? SUMMIT THERAPEU/S has a market capitalization of $46.81 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.View Additional Information About SUMMIT THERAPEU/S. What is SUMMIT THERAPEU/S's official website? The official website for SUMMIT THERAPEU/S is http://www.summitplc.com/. How can I contact SUMMIT THERAPEU/S? SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected] MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 269 (Vote Outperform)Underperform Votes: 314 (Vote Underperform)Total Votes: 583MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What does the Dogs of the Dow mean?
